Literature DB >> 20035570

Arsenic-induced carcinogenesis--oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment.

Kirk T Kitchin1, Rory Conolly.   

Abstract

Exposure to inorganic arsenic (iAs) induces cancer in human lungs, urinary bladder, skin, kidney, and liver, with the majority of deaths from lung and bladder cancer. To date, cancer risk assessments for iAs have not relied on mechanistic data, as we have lacked sufficient understanding of arsenic's pharmacokinetics and mode(s) of carcinogenic action (MOA). Furthermore, while there are vast amounts of toxicological data on iAs, relatively little of it has been collected using experimental designs that efficiently support development of biologically based dose-response (BBDR) models and subsequently risk assessment. This review outlines an efficient approach to the development of a BBDR model for iAs that would reduce uncertainties in its cancer risk assessment. This BBDR-based approach is illustrated by using oxidative stress as the carcinogenic MOA for iAs but would be generically applicable to other MOAs. Six major research needs that will facilitate BBDR model development for arsenic-induced cancer are (1) MOA research, which is needed to reduce the uncertainty in risk assessment; (2) development and integration of the pharmacodynamic component (MOA) of the BBDR model; (3) dose-response and extrapolation model selection; (4) the determination of internal human speciated arsenical concentrations to improve physiologically based pharmacokinetic (PBPK) models; (5) animal models of arsenic carcinogenesis; and (6) the determination of the low dose human relationship for death from cancer, particularly in lungs and urinary bladder. The major parts of the BBDR model are arsenic exposure, a physiologically based pharmacokinetic model, reactive species, antioxidant defenses, oxidative stress, cytotoxicity, growth factors, transcription factors, DNA damage, chromosome damage, cell proliferation, mutation accumulation, and cancer. The BBDR model will need to be developed concurrently with data collection so that model uncertainties can be identified and addressed through an iterative process of targeted additional research.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20035570     DOI: 10.1021/tx900343d

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  53 in total

Review 1.  State of the science review of the health effects of inorganic arsenic: Perspectives for future research.

Authors:  Paul B Tchounwou; Clement G Yedjou; Udensi K Udensi; Maricica Pacurari; Jacqueline J Stevens; Anita K Patlolla; Felicite Noubissi; Sanjay Kumar
Journal:  Environ Toxicol       Date:  2018-12-04       Impact factor: 4.119

2.  Arsenic, stem cells, and the developmental basis of adult cancer.

Authors:  Erik J Tokar; Wei Qu; Michael P Waalkes
Journal:  Toxicol Sci       Date:  2010-11-11       Impact factor: 4.849

3.  Arsenic exposure and toxicology: a historical perspective.

Authors:  Michael F Hughes; Barbara D Beck; Yu Chen; Ari S Lewis; David J Thomas
Journal:  Toxicol Sci       Date:  2011-07-12       Impact factor: 4.849

4.  Ethanol enhances tumor angiogenesis in vitro induced by low-dose arsenic in colon cancer cells through hypoxia-inducible factor 1 alpha pathway.

Authors:  Lei Wang; Young-Ok Son; Songze Ding; Xin Wang; John Andrew Hitron; Amit Budhraja; Jeong-Chae Lee; Qinchen Lin; Pratheeshkumar Poyil; Zhuo Zhang; Jia Luo; Xianglin Shi
Journal:  Toxicol Sci       Date:  2012-08-07       Impact factor: 4.849

5.  Resveratrol protects against arsenic trioxide-induced oxidative damage through maintenance of glutathione homeostasis and inhibition of apoptotic progression.

Authors:  Chengzhi Chen; Xuejun Jiang; Yanhao Lai; Yuan Liu; Zunzhen Zhang
Journal:  Environ Mol Mutagen       Date:  2014-10-23       Impact factor: 3.216

6.  Identification of novel gene targets and putative regulators of arsenic-associated DNA methylation in human urothelial cells and bladder cancer.

Authors:  Julia E Rager; Sloane K Tilley; Samantha E Tulenko; Lisa Smeester; Paul D Ray; Andrew Yosim; Jenna M Currier; María C Ishida; Maria Del Carmen González-Horta; Blanca Sánchez-Ramírez; Lourdes Ballinas-Casarrubias; Daniela S Gutiérrez-Torres; Zuzana Drobná; Luz M Del Razo; Gonzalo G García-Vargas; William Y Kim; Yi-Hui Zhou; Fred A Wright; Miroslav Stýblo; Rebecca C Fry
Journal:  Chem Res Toxicol       Date:  2015-06-03       Impact factor: 3.739

7.  Monomethylarsonous acid (MMA+3) Inhibits IL-7 Signaling in Mouse Pre-B Cells.

Authors:  Peace C Ezeh; Huan Xu; Fredine T Lauer; Ke Jian Liu; Laurie G Hudson; Scott W Burchiel
Journal:  Toxicol Sci       Date:  2015-10-30       Impact factor: 4.849

8.  Poly(ADP-ribose) polymerase-1 inhibition by arsenite promotes the survival of cells with unrepaired DNA lesions induced by UV exposure.

Authors:  Xu-Jun Qin; Wenlan Liu; Ying-Na Li; Xi Sun; Chun-Xu Hai; Laurie G Hudson; Ke Jian Liu
Journal:  Toxicol Sci       Date:  2012-03-02       Impact factor: 4.849

9.  Methylarsonous acid causes oxidative DNA damage in cells independent of the ability to biomethylate inorganic arsenic.

Authors:  Erik J Tokar; Chikara Kojima; Michael P Waalkes
Journal:  Arch Toxicol       Date:  2013-10-05       Impact factor: 5.153

10.  Transcriptional Modulation of the ERK1/2 MAPK and NF-κB Pathways in Human Urothelial Cells After Trivalent Arsenical Exposure: Implications for Urinary Bladder Cancer.

Authors:  Kathryn A Bailey; Kathleen Wallace; Lisa Smeester; Sheau-Fung Thai; Douglas C Wolf; Stephen W Edwards; Rebecca C Fry
Journal:  J Can Res Updates       Date:  2012-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.